<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
<url>
<loc>https://stoqly.net/news/dae-macquarie-airfinance-acquisition-2026</loc>
<news:news>
<news:publication><news:name>Stoqly</news:name><news:language>en</news:language></news:publication>
<news:publication_date>2026-11-10T15:48:01+00:00</news:publication_date>
<news:title>DAE completes $9 billion Macquarie AirFinance acquisition as revenue rises</news:title>
</news:news>
</url>
<url>
<loc>https://stoqly.net/es/news/dae-macquarie-airfinance-acquisition-2026</loc>
<news:news>
<news:publication><news:name>Stoqly</news:name><news:language>es</news:language></news:publication>
<news:publication_date>2026-11-10T15:48:01+00:00</news:publication_date>
<news:title>DAE completa la adquisición de Macquarie AirFinance por 9.000 millones de dólares</news:title>
</news:news>
</url>
<url>
<loc>https://stoqly.net/news/maxcyte-akron-bioproducts-acquisition-2026</loc>
<news:news>
<news:publication><news:name>Stoqly</news:name><news:language>en</news:language></news:publication>
<news:publication_date>2026-11-10T15:05:00+00:00</news:publication_date>
<news:title>MaxCyte to acquire Akron BioProducts in cell-therapy materials expansion</news:title>
</news:news>
</url>
<url>
<loc>https://stoqly.net/es/news/maxcyte-akron-bioproducts-acquisition-2026</loc>
<news:news>
<news:publication><news:name>Stoqly</news:name><news:language>es</news:language></news:publication>
<news:publication_date>2026-11-10T15:05:00+00:00</news:publication_date>
<news:title>MaxCyte comprará Akron BioProducts para ampliar su negocio de materiales de terapia celular</news:title>
</news:news>
</url>
<url>
<loc>https://stoqly.net/news/cormedix-heron-assets-acquisition-2026</loc>
<news:news>
<news:publication><news:name>Stoqly</news:name><news:language>en</news:language></news:publication>
<news:publication_date>2026-11-10T12:04:00+00:00</news:publication_date>
<news:title>CorMedix to acquire Heron assets for $145 million cash and stock</news:title>
</news:news>
</url>
<url>
<loc>https://stoqly.net/es/news/cormedix-heron-assets-acquisition-2026</loc>
<news:news>
<news:publication><news:name>Stoqly</news:name><news:language>es</news:language></news:publication>
<news:publication_date>2026-11-10T12:04:00+00:00</news:publication_date>
<news:title>CorMedix comprará activos de Heron por 145 millones de dólares en efectivo y acciones</news:title>
</news:news>
</url>
<url>
<loc>https://stoqly.net/news/charles-river-frontage-bioanalysis-acquisition</loc>
<news:news>
<news:publication><news:name>Stoqly</news:name><news:language>en</news:language></news:publication>
<news:publication_date>2026-11-09T18:09:00+00:00</news:publication_date>
<news:title>Charles River to acquire Frontage bioanalysis operations for $470 million</news:title>
</news:news>
</url>
<url>
<loc>https://stoqly.net/es/news/charles-river-frontage-bioanalysis-acquisition</loc>
<news:news>
<news:publication><news:name>Stoqly</news:name><news:language>es</news:language></news:publication>
<news:publication_date>2026-11-09T18:09:00+00:00</news:publication_date>
<news:title>Charles River comprará las operaciones de bioanálisis de Frontage por 470 millones de dólares</news:title>
</news:news>
</url>
</urlset>
